NO822122L - Fremgangsmaate for fremstilling av amidobenzamider - Google Patents
Fremgangsmaate for fremstilling av amidobenzamiderInfo
- Publication number
- NO822122L NO822122L NO822122A NO822122A NO822122L NO 822122 L NO822122 L NO 822122L NO 822122 A NO822122 A NO 822122A NO 822122 A NO822122 A NO 822122A NO 822122 L NO822122 L NO 822122L
- Authority
- NO
- Norway
- Prior art keywords
- group
- dimethylaminomethylfuran
- ylmethylthio
- ethyl
- mol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 31
- -1 phenyl- Chemical group 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- JFGCGQJHMUYGLU-UHFFFAOYSA-N 2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethanamine Chemical compound CN(C)CC1=CC=C(CSCCN)O1 JFGCGQJHMUYGLU-UHFFFAOYSA-N 0.000 claims description 9
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- YYDIGPGUISOOIJ-UHFFFAOYSA-N 1-(2h-pyridin-1-yloxy)-2h-pyridine Chemical group C1C=CC=CN1ON1C=CC=CC1 YYDIGPGUISOOIJ-UHFFFAOYSA-N 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 28
- 239000003826 tablet Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 229960001340 histamine Drugs 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000004480 active ingredient Substances 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 229960001380 cimetidine Drugs 0.000 description 11
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 8
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 8
- 229960000620 ranitidine Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 239000000499 gel Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000007937 lozenge Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 230000009291 secondary effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229960003604 testosterone Drugs 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IQEIBIZCGRTILA-UHFFFAOYSA-N 3-(benzenesulfonamido)-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]benzamide Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 IQEIBIZCGRTILA-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- MPGIQLJTSXAKSM-UHFFFAOYSA-N 3-(butylsulfonylamino)-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]benzamide Chemical compound CCCCS(=O)(=O)NC1=CC=CC(C(=O)NCCSCC=2OC(CN(C)C)=CC=2)=C1 MPGIQLJTSXAKSM-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000008469 Peptic Ulcer Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940054066 benzamide antipsychotics Drugs 0.000 description 2
- 150000003936 benzamides Chemical class 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000005518 carboxamido group Chemical group 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- XAHFWXWXESMIPV-UHFFFAOYSA-N oxmetidine Chemical compound CC1=NC=N[C]1CSCCNC(NC1=O)=NC=C1CC1=CC=C(OCO2)C2=C1 XAHFWXWXESMIPV-UHFFFAOYSA-N 0.000 description 2
- 229950006792 oxmetidine Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- SFMCQVUGTBOHCL-UHFFFAOYSA-N (4-nitrophenyl) 3-(butylsulfonylamino)benzoate Chemical compound CCCCS(=O)(=O)NC1=CC=CC(C(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 SFMCQVUGTBOHCL-UHFFFAOYSA-N 0.000 description 1
- ZTVUGKLODJJIND-UHFFFAOYSA-N (4-nitrophenyl) 3-(ethylsulfonylamino)benzoate Chemical compound CCS(=O)(=O)NC1=CC=CC(C(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 ZTVUGKLODJJIND-UHFFFAOYSA-N 0.000 description 1
- FRFDFQSXMXPBSU-UHFFFAOYSA-N (4-nitrophenyl) 3-(methanesulfonamido)benzoate Chemical compound CS(=O)(=O)NC1=CC=CC(C(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 FRFDFQSXMXPBSU-UHFFFAOYSA-N 0.000 description 1
- WSJLWGBDMVVKIR-UHFFFAOYSA-N (4-nitrophenyl) 3-acetamidobenzoate Chemical compound CC(=O)NC1=CC=CC(C(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)=C1 WSJLWGBDMVVKIR-UHFFFAOYSA-N 0.000 description 1
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KEDVUOWPLAHMLZ-UHFFFAOYSA-N 1-cyano-3-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]-2-prop-2-ynylguanidine Chemical compound CC=1NC=NC=1CSCCNC(NC#N)=NCC#C KEDVUOWPLAHMLZ-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 description 1
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical class NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- RELBUFSHELNQKC-UHFFFAOYSA-N 3-(benzenesulfonamido)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=CC=CC=2)=C1 RELBUFSHELNQKC-UHFFFAOYSA-N 0.000 description 1
- MLQHHLKDYFZRIP-UHFFFAOYSA-N 3-(butanoylamino)-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CCCC(=O)NC1=CC=CC(C(=O)NCCSCC=2OC(CN(C)C)=CC=2)=C1 MLQHHLKDYFZRIP-UHFFFAOYSA-N 0.000 description 1
- NNYMOONPKZDVLC-UHFFFAOYSA-N 3-(pyrazine-2-carbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C=2N=CC=NC=2)=C1 NNYMOONPKZDVLC-UHFFFAOYSA-N 0.000 description 1
- LYCKQCPHDDFKEL-UHFFFAOYSA-N 3-(pyridin-3-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2C=NC=CC=2)=C1 LYCKQCPHDDFKEL-UHFFFAOYSA-N 0.000 description 1
- CFQHNZSRMWNVCF-UHFFFAOYSA-N 3-(pyridine-2-carbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C=2N=CC=CC=2)=C1 CFQHNZSRMWNVCF-UHFFFAOYSA-N 0.000 description 1
- ZPXHGRCNSBEEOL-UHFFFAOYSA-N 3-(pyridine-3-carbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C=2C=NC=CC=2)=C1 ZPXHGRCNSBEEOL-UHFFFAOYSA-N 0.000 description 1
- MCLRAQYEHWJHFQ-UHFFFAOYSA-N 3-(pyridine-4-carbonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C=2C=CN=CC=2)=C1 MCLRAQYEHWJHFQ-UHFFFAOYSA-N 0.000 description 1
- HGLIUHOTRGFJQZ-UHFFFAOYSA-N 3-(thiophen-2-ylsulfonylamino)benzoic acid Chemical compound OC(=O)C1=CC=CC(NS(=O)(=O)C=2SC=CC=2)=C1 HGLIUHOTRGFJQZ-UHFFFAOYSA-N 0.000 description 1
- OAAIMQOVHKDXLS-UHFFFAOYSA-N 3-acetamido-n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NC(C)=O)=C1 OAAIMQOVHKDXLS-UHFFFAOYSA-N 0.000 description 1
- WXTOAZQBWHSIQN-UHFFFAOYSA-N 3-benzamidobenzoic acid Chemical compound OC(=O)C1=CC=CC(NC(=O)C=2C=CC=CC=2)=C1 WXTOAZQBWHSIQN-UHFFFAOYSA-N 0.000 description 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- XGEWYLYORRUIDY-UHFFFAOYSA-N OC(=O)C(O)=O.OC(=O)C(O)=O.O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NC(=O)C=2C=CN=CC=2)=C1 Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O.O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NC(=O)C=2C=CN=CC=2)=C1 XGEWYLYORRUIDY-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001974 anti-anabolic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- CECGBBNIUDXSHK-UHFFFAOYSA-N benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.NC(=O)C1=CC=CC=C1 CECGBBNIUDXSHK-UHFFFAOYSA-N 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229950007285 etintidine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- JQIMQUYNGAUDJS-UHFFFAOYSA-N n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-3-(ethylsulfonylamino)benzamide Chemical compound CCS(=O)(=O)NC1=CC=CC(C(=O)NCCSCC=2OC(CN(C)C)=CC=2)=C1 JQIMQUYNGAUDJS-UHFFFAOYSA-N 0.000 description 1
- OYYXVCBZDLQQIX-UHFFFAOYSA-N n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-3-(methanesulfonamido)benzamide Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NS(C)(=O)=O)=C1 OYYXVCBZDLQQIX-UHFFFAOYSA-N 0.000 description 1
- AQIIUBOXGIIDAT-UHFFFAOYSA-N n-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-4-sulfamoylbenzamide Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=C(S(N)(=O)=O)C=C1 AQIIUBOXGIIDAT-UHFFFAOYSA-N 0.000 description 1
- BXGVARNVLDZAEF-UHFFFAOYSA-N n-[3-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylcarbamoyl]phenyl]pyrazine-2-carboxamide Chemical compound O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NC(=O)C=2N=CC=NC=2)=C1 BXGVARNVLDZAEF-UHFFFAOYSA-N 0.000 description 1
- BUCULQWFEYJAIY-UHFFFAOYSA-N n-[3-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethylcarbamoyl]phenyl]pyridine-2-carboxamide;oxalic acid Chemical compound OC(=O)C(O)=O.O1C(CN(C)C)=CC=C1CSCCNC(=O)C1=CC=CC(NC(=O)C=2N=CC=CC=2)=C1 BUCULQWFEYJAIY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-L pamoate(2-) Chemical compound C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-L 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8113420A FR2509305B1 (fr) | 1981-07-08 | 1981-07-08 | Benzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant |
FR8119967A FR2515181A1 (fr) | 1981-10-23 | 1981-10-23 | Amidobenzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant |
FR8123084A FR2518097A1 (fr) | 1981-12-10 | 1981-12-10 | Amidobenzamide, procede pour sa preparation et compositions pharmaceutiques la renfermant |
Publications (1)
Publication Number | Publication Date |
---|---|
NO822122L true NO822122L (no) | 1983-01-10 |
Family
ID=27251063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO822122A NO822122L (no) | 1981-07-08 | 1982-06-24 | Fremgangsmaate for fremstilling av amidobenzamider |
Country Status (17)
Country | Link |
---|---|
US (1) | US4439444A (pt) |
EP (1) | EP0069664B1 (pt) |
AR (1) | AR231288A1 (pt) |
AU (1) | AU547405B2 (pt) |
CA (1) | CA1190927A (pt) |
DD (1) | DD202433A5 (pt) |
DE (1) | DE3262870D1 (pt) |
DK (1) | DK305982A (pt) |
ES (1) | ES513792A0 (pt) |
FI (1) | FI822408L (pt) |
GR (1) | GR76007B (pt) |
HU (1) | HU189599B (pt) |
IL (1) | IL66227A (pt) |
NO (1) | NO822122L (pt) |
NZ (1) | NZ201197A (pt) |
PT (1) | PT75209B (pt) |
YU (1) | YU149482A (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2531706A1 (fr) * | 1982-08-13 | 1984-02-17 | Sanofi Sa | Benzamides, leurs sels, procede pour leur preparation et compositions pharmaceutiques les renfermant |
GB8422461D0 (en) * | 1984-09-05 | 1984-10-10 | Wyeth John & Brother Ltd | Pyridine derivatives |
US4912101A (en) * | 1987-03-13 | 1990-03-27 | Fujirebio Kabushiki Kaisha | 4-aminomethyl-pyridyl-2-oxy derivatives having anti-ulcer activity |
GB8921792D0 (en) * | 1989-09-27 | 1989-11-08 | May & Baker Ltd | New compositions of matter |
PL309038A1 (en) * | 1992-11-20 | 1995-09-18 | Kaken Pharma Co Ltd | Acetamide derivative |
BRPI0611863B1 (pt) * | 2005-06-22 | 2021-11-23 | Plexxikon, Inc | Composto, bem como composição e kit compreendendo o mesmo, composto intermediário na preparação do mesmo, método para tratamento e uso do mesmo |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
MY172424A (en) | 2009-04-03 | 2019-11-25 | Hoffmann La Roche | Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
BR112012012156A2 (pt) | 2009-11-06 | 2015-09-08 | Plexxikon Inc | compostos e métodos para modulação de cinase, e indicações para esta |
TR201816421T4 (tr) | 2011-02-07 | 2018-11-21 | Plexxikon Inc | Kinaz modülasyonu için bileşikler ve metotlar ve bunların endikasyonları. |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
EP4196793A1 (en) | 2020-08-11 | 2023-06-21 | Université de Strasbourg | H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2835695A1 (de) * | 1977-08-29 | 1979-03-15 | Yamanouchi Pharma Co Ltd | Neue heterocyclische verbindungen, verfahren zu ihrer herstellung und arzneimittel, die diese enthalten |
JPS5681578A (en) * | 1979-12-07 | 1981-07-03 | Shionogi & Co Ltd | Novel thioalkyl amide derivative |
-
1982
- 1982-06-23 AU AU85134/82A patent/AU547405B2/en not_active Ceased
- 1982-06-24 NO NO822122A patent/NO822122L/no unknown
- 1982-07-02 GR GR68627A patent/GR76007B/el unknown
- 1982-07-05 IL IL66227A patent/IL66227A/xx unknown
- 1982-07-05 DE DE8282401252T patent/DE3262870D1/de not_active Expired
- 1982-07-05 EP EP82401252A patent/EP0069664B1/fr not_active Expired
- 1982-07-06 AR AR289895A patent/AR231288A1/es active
- 1982-07-07 FI FI822408A patent/FI822408L/fi not_active Application Discontinuation
- 1982-07-07 NZ NZ201197A patent/NZ201197A/en unknown
- 1982-07-07 US US06/396,100 patent/US4439444A/en not_active Expired - Fee Related
- 1982-07-07 CA CA000406813A patent/CA1190927A/en not_active Expired
- 1982-07-07 DD DD82241472A patent/DD202433A5/de unknown
- 1982-07-07 HU HU822215A patent/HU189599B/hu unknown
- 1982-07-07 PT PT75209A patent/PT75209B/pt unknown
- 1982-07-07 ES ES513792A patent/ES513792A0/es active Granted
- 1982-07-07 DK DK305982A patent/DK305982A/da not_active Application Discontinuation
- 1982-07-08 YU YU01494/82A patent/YU149482A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US4439444A (en) | 1984-03-27 |
NZ201197A (en) | 1985-01-31 |
DK305982A (da) | 1983-01-09 |
DE3262870D1 (en) | 1985-05-09 |
AU8513482A (en) | 1983-01-13 |
DD202433A5 (de) | 1983-09-14 |
CA1190927A (en) | 1985-07-23 |
IL66227A (en) | 1985-07-31 |
PT75209B (fr) | 1984-06-27 |
FI822408A0 (fi) | 1982-07-07 |
FI822408L (fi) | 1983-01-09 |
GR76007B (pt) | 1984-08-03 |
YU149482A (en) | 1984-12-31 |
ES8308326A1 (es) | 1983-08-16 |
AU547405B2 (en) | 1985-10-17 |
AR231288A1 (es) | 1984-10-31 |
EP0069664A1 (fr) | 1983-01-12 |
HU189599B (en) | 1986-07-28 |
ES513792A0 (es) | 1983-08-16 |
EP0069664B1 (fr) | 1985-04-03 |
IL66227A0 (en) | 1982-11-30 |
PT75209A (fr) | 1982-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR890002290B1 (ko) | 피페라진 유도체 및 그의 제조방법 | |
NO822122L (no) | Fremgangsmaate for fremstilling av amidobenzamider | |
NO811680L (no) | Fremgangsmaate for fremstilling av pyridoksin-derivater | |
US4169154A (en) | Method of treating depression with thiourea derivatives | |
CA1114379A (en) | Piperidino-phthalazines | |
US4096276A (en) | Thiourea derivatives for treating hypertension | |
US5635511A (en) | Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds. | |
US4330546A (en) | 3-Aryl-3-aryloxypropylamines | |
EP0039989B1 (en) | Pyrimidone derivatives, processes for their preparation and pharmaceutical compositions containing them | |
US4440773A (en) | Pyridylalkylenethiopridyl, -tetrahydropyridyl and -pyridinium compounds | |
US4060621A (en) | Pyridyl alkylguanidine compounds | |
US4492711A (en) | Benzamides, their salts, and pharmaceutical compositions containing them | |
EP0113910A1 (en) | Isocarbostyril derivatives, processes for their preparation and pharmaceutical compositions containing them | |
KR860001314B1 (ko) | 티오알킬아미드 1-옥시드 니코틴산 및 그 염의 제조방법 | |
US4113776A (en) | 1-(2-Aminoethyl)-3-(2,6-dihalophenyl)guanidines | |
US4150138A (en) | Method of reducing blood pressure with thiourea derivatives and guanidine derivatives | |
US4501747A (en) | Certain amide derivatives of 2-guanidino-thiazoles and compositions containing same | |
CS229935B2 (en) | Production method of 3-amido-n-(2(5dimethylaminomethylfura-2-ylemthylthyltio)benzamide | |
US4224331A (en) | Derivatives of 2-pyridylthiourea and pharmaceutical compositions | |
US4415575A (en) | Suppression of gastric acid secretion using pyrimidylcarbamates | |
AT345291B (de) | Verfahren zur herstellung von neuen cyclisch substituierten derivaten des 1-amino-2-propanols und deren salzen | |
JPS58208280A (ja) | アミド類、その塩、それらの製造方法およびそれらを含有する薬学的組成物 | |
FR2518097A1 (fr) | Amidobenzamide, procede pour sa preparation et compositions pharmaceutiques la renfermant | |
FR2528428A1 (fr) | Benzamides, procede pour leur preparation et compositions pharmaceutiques les renfermant | |
FR2531705A1 (fr) | Amidobenzamides, leurs sels, procede pour leur preparation et compositions pharmaceutiques les renfermant |